Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-4847-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$669.89 million
Profitability
Miscellaneous
Employees1,464
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions
What is Taro Pharmaceutical Industries' stock symbol?
Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."
How often does Taro Pharmaceutical Industries pay dividends? What is the dividend yield for Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries declared a dividend on Monday, November 5th. Shareholders of record on Tuesday, December 11th will be paid a dividend of $12.81 per share on Friday, December 28th. The ex-dividend date of this dividend is Monday, December 10th. View Taro Pharmaceutical Industries' Dividend History.
How were Taro Pharmaceutical Industries' earnings last quarter?
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its quarterly earnings results on Thursday, August, 8th. The company reported $1.72 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.96 by $0.24. The firm had revenue of $161.30 million for the quarter, compared to analysts' expectations of $169.80 million. Taro Pharmaceutical Industries had a net margin of 41.49% and a return on equity of 13.90%. View Taro Pharmaceutical Industries' Earnings History.
When is Taro Pharmaceutical Industries' next earnings date?
What price target have analysts set for TARO?
1 equities research analysts have issued 12 month price objectives for Taro Pharmaceutical Industries' shares. Their predictions range from $105.00 to $105.00. On average, they expect Taro Pharmaceutical Industries' stock price to reach $105.00 in the next year. This suggests a possible upside of 38.6% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.
What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.
What are Wall Street analysts saying about Taro Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Taro Pharmaceutical Industries stock:
- 1. According to Zacks Investment Research, "Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals. " (10/15/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a price objective of $115 per share, based on a forward EPS multiple of 15.5x applied to our current fiscal 2019 EPS forecast of $7.40 per share." (12/10/2018)
Has Taro Pharmaceutical Industries been receiving favorable news coverage?
News headlines about TARO stock have trended very positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Taro Pharmaceutical Industries.
Who are some of Taro Pharmaceutical Industries' key competitors?
Some companies that are related to Taro Pharmaceutical Industries include Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY) and Sarepta Therapeutics (SRPT).
What other stocks do shareholders of Taro Pharmaceutical Industries own?
Who are Taro Pharmaceutical Industries' key executives?
Taro Pharmaceutical Industries' management team includes the folowing people:
- Mr. Uday V. Baldota, CEO & Director (Age 49)
- Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
- Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
- Mr. Itzik Baruch, VP of Technical Services (Age 56)
- Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)
Who are Taro Pharmaceutical Industries' major shareholders?
Taro Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional investors include CLARET ASSET MANAGEMENT Corp (0.22%).
Which major investors are selling Taro Pharmaceutical Industries stock?
TARO stock was sold by a variety of institutional investors in the last quarter, including CLARET ASSET MANAGEMENT Corp.
How do I buy shares of Taro Pharmaceutical Industries?
Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Taro Pharmaceutical Industries' stock price today?
One share of TARO stock can currently be purchased for approximately $75.76.
How big of a company is Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries has a market capitalization of $2.92 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries.
What is Taro Pharmaceutical Industries' official website?
How can I contact Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]
MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
